5-Aminolevulinic acid HCl

Catalog No.S2553

For research use only.

5-Aminolevulinic Acid HCl is an intermediate in the porphyrin synthesis pathway, used as a photosensitizing agent and a antineoplastic agent.

5-Aminolevulinic acid HCl Chemical Structure

CAS No. 5451-09-2

Selleck's 5-Aminolevulinic acid HCl has been cited by 7 Publications

Purity & Quality Control

Related Other Products

Biological Activity

Description 5-Aminolevulinic Acid HCl is an intermediate in the porphyrin synthesis pathway, used as a photosensitizing agent and a antineoplastic agent.
In vitro

5-aminolevulinic acid (5-ALA)-Photodynamic therapy (PDT) results in down regulation of nuclear factor kappa B (NFkappaB) and baculovirus inhibitor-of-apoptosis repeat containing-3 (BIRC-3) protein. 5-aminolevulinic acid (5-ALA)-Photodynamic therapy (PDT) causes increase in Bax:Bcl-2 ratio and mitochondrial release of cytochrome c and apoptosis-inducing factor (AIF). [1] 5-aminolevulinic acid yields reactive oxygen species upon metal-catalyzed oxidation and causes in vivo and in vitro impairment of rat liver mitochondria and DNA damage. 5-aminolevulinic acid induces a dose-dependent damage in nuclear and mitochondrial DNA in human SVNF fibroblasts and rat PC12 cells. [2] 5-aminolevulinic acid dose-dependently decreases cAMP levels (maximal inhibition of 38%, at 1 mM), due to an inhibition of basaladenylate cyclase activity. 5-aminolevulinic acid also inhibits fluoride- and Gpp(NH)p-stimulated, but not the forskolin-stimulated adenylate cyclase activity. 5-aminolevulinic acid also inhibits the activity of adenylate cyclase in membranes isolated from rat cortex and striatum and from human cortex. [3] 5-aminolevulinic acid (0-3mM) dose-dependently inhibits glutamate uptake by astrocyte cultures. 5-aminolevulinic acid significantly reduces both the K(m) and V(max) of glutamate uptake indicating an uncompetitive inhibition. 5-aminolevulinic acid significantly increases astrocyte lipoperoxidation in astrocytes incubated under these conditions. [4] 5-aminolevulinic acid mediated sonodynamic therapy exhibits synergistic apoptotic effects on THP-1 macrophages, involving excessive intracellular reactive oxygen species generation and MMP loss. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 34 mg/mL
(202.87 mM)
Water 34 mg/mL
(202.87 mM)
Ethanol 6 mg/mL
(35.8 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 167.59
Formula

C5H9NO3.HCl

CAS No. 5451-09-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C(CC(=O)O)C(=O)CN.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04626661 Recruiting Device: COMET measurement system Mitochondrial Oxygenation Measurement|Measurement Error|Healthy Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research|Leiden University Medical Center June 15 2020 --
NCT00241670 Completed Drug: 5-aminolevulinic acid (5-ALA) Brain Cancer|Brain Tumors|Cancer of Brain|Primary Brain Tumors|Brain Tumor Primary medac GmbH October 1999 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy 5-Aminolevulinic acid HCl | 5-Aminolevulinic acid HCl ic50 | 5-Aminolevulinic acid HCl price | 5-Aminolevulinic acid HCl cost | 5-Aminolevulinic acid HCl solubility dmso | 5-Aminolevulinic acid HCl purchase | 5-Aminolevulinic acid HCl manufacturer | 5-Aminolevulinic acid HCl research buy | 5-Aminolevulinic acid HCl order | 5-Aminolevulinic acid HCl mouse | 5-Aminolevulinic acid HCl chemical structure | 5-Aminolevulinic acid HCl mw | 5-Aminolevulinic acid HCl molecular weight | 5-Aminolevulinic acid HCl datasheet | 5-Aminolevulinic acid HCl supplier | 5-Aminolevulinic acid HCl in vitro | 5-Aminolevulinic acid HCl cell line | 5-Aminolevulinic acid HCl concentration | 5-Aminolevulinic acid HCl nmr